Skip to main content

Innogenetics' First-Half '08 Revenues Rise 12 Percent

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Innogenetics today reported that its first-half 2008 revenues rose 12 percent, but its net loss inched up 2.6 percent on restructuring and impairment charges.
 
The Gent, Belgium-based company brought in revenues of €30.6 million ($45.1 million) for the six-month period ended June 30, compared with revenues of €27.4 million in the first half of 2007. Innogenetics said that its diagnostic product sales rose 8.4 percent year over year to €25.8 million, driven by sales of infectious diseases and Alzheimer’s disease diagnostics.
 
The firm’s first-half net loss was €8 million, or €.26 per share, compared to a net loss of €7.8 million, or €.25 per share, for the comparable period a year ago.
 
The 2008 first-half results include €8 million in non-recurring restructuring and impairment charges related to the termination of the firm’s GENimmune therapeutic activities. It also includes a $9.5 million settlement with Abbott Laboratories, under which Abbott licensed rights to Innogenetics’ hepatitis C genotyping patents. Innogenetics said that it received all cash from the settlement during the first half of this year.
 
The firm finished the first half with €15.7 million in cash.
 
Innogenetics is in the process of being acquired by Solvay Pharmaceuticals for roughly $316 million. Gen-Probe had also bid to acquire Innogenetics but pulled out after Solvay raised its offering price for the firm.
 
 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.